CLINICAL TRIALS PROFILE FOR CLONIDINE HYDROCHLORIDE AND CHLORTHALIDONE

All Clinical Trials for CLONIDINE HYDROCHLORIDE AND CHLORTHALIDONE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00007592 ↗	Hypertension Screening and Treatment Program	Completed	US Department of Veterans Affairs		1989-06-01	Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00007592 ↗	Hypertension Screening and Treatment Program	Completed	VA Office of Research and Development		1989-06-01	Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT01643434 ↗	Resistant Hypertension Optimal Treatment	Unknown status	Conselho Nacional de Desenvolvimento Científico e Tecnológico	Phase 4	2012-08-01	Resistant hypertension (ReHy) is an emerging clinical and public health problem which tends to increase because populations are living longer and there is a growing global epidemic of obesity, diabetes and sleep apnea. It is also tempting to speculate that the excessive dietary salt ingestion reported in many countries can contribute substantially to the risk of ReHy development. ReHy is defined as persistent high blood pressure (above the target goal) in spite of the use of at least 3 antihypertensive agents of different classes, one of them must being diuretics. Data regarding the exact prevalence of ReHy are very limited. In addition, little data is available about 3-drug combinations but a simplified treatment algorithm has demonstrated that a combination of a diuretic plus an angiotensin-converting enzyme inhibitors (ACEi) or an angiotensin-receptor blocker (ARB) plus diuretic, adding a calcium channel blocker when necessary, controlled 64% of hypertensive patients and, in addition, was even more efficient than the current guideline-based management. By contrast, the fourth drug to be added-on the triple regimen is still controversial and guided by empirical choices or personal preferences. Recent studies suggest the emerging role of spironolactone as the "first-line" fourth drug for treating resistant hypertension. Conversely, because of the pathophysiological rationale, others have proposed the use of β-blockers or even centrally acting agents for managing the sympathetic hyperactivity. The present concerns about the limited blood pressure reducing effect of β-blockers, especially in elderly people, the potent effect of centrally acting agents and our personal experience are pointing to clonidine as the fourth drug to be added-on to a multidrug combination for reaching optimal blood pressure in patients with ReHy. Nevertheless, no studies have been performed comparing, head-to-head, which one is the best fourth drug (spironolactone or clonidine) to be added-on to a common used multidrug combination in order to treat this condition. Therefore, the principal objectives of the ReHOT Trial are to assess prospectively: (1) the prevalence of ReHy in a cohort of outpatients with stage II hypertension; (2) the effect of spironolactone on blood pressure, in comparison to clonidine, when added to a multidrug combination consisting of chlorthalidone plus ACEi (or ARB) plus amlodipine, all of 3 up-titrated to the highest dose; (3) the role of measuring sympathetic nervous system activity and renin-angiotensin-aldosterone activity on predicting the response of blood pressure to spironolactone and clonidine.
NCT01643434 ↗	Resistant Hypertension Optimal Treatment	Unknown status	Instituto do Coracao	Phase 4	2012-08-01	Resistant hypertension (ReHy) is an emerging clinical and public health problem which tends to increase because populations are living longer and there is a growing global epidemic of obesity, diabetes and sleep apnea. It is also tempting to speculate that the excessive dietary salt ingestion reported in many countries can contribute substantially to the risk of ReHy development. ReHy is defined as persistent high blood pressure (above the target goal) in spite of the use of at least 3 antihypertensive agents of different classes, one of them must being diuretics. Data regarding the exact prevalence of ReHy are very limited. In addition, little data is available about 3-drug combinations but a simplified treatment algorithm has demonstrated that a combination of a diuretic plus an angiotensin-converting enzyme inhibitors (ACEi) or an angiotensin-receptor blocker (ARB) plus diuretic, adding a calcium channel blocker when necessary, controlled 64% of hypertensive patients and, in addition, was even more efficient than the current guideline-based management. By contrast, the fourth drug to be added-on the triple regimen is still controversial and guided by empirical choices or personal preferences. Recent studies suggest the emerging role of spironolactone as the "first-line" fourth drug for treating resistant hypertension. Conversely, because of the pathophysiological rationale, others have proposed the use of β-blockers or even centrally acting agents for managing the sympathetic hyperactivity. The present concerns about the limited blood pressure reducing effect of β-blockers, especially in elderly people, the potent effect of centrally acting agents and our personal experience are pointing to clonidine as the fourth drug to be added-on to a multidrug combination for reaching optimal blood pressure in patients with ReHy. Nevertheless, no studies have been performed comparing, head-to-head, which one is the best fourth drug (spironolactone or clonidine) to be added-on to a common used multidrug combination in order to treat this condition. Therefore, the principal objectives of the ReHOT Trial are to assess prospectively: (1) the prevalence of ReHy in a cohort of outpatients with stage II hypertension; (2) the effect of spironolactone on blood pressure, in comparison to clonidine, when added to a multidrug combination consisting of chlorthalidone plus ACEi (or ARB) plus amlodipine, all of 3 up-titrated to the highest dose; (3) the role of measuring sympathetic nervous system activity and renin-angiotensin-aldosterone activity on predicting the response of blood pressure to spironolactone and clonidine.

Clinical Trial Conditions for CLONIDINE HYDROCHLORIDE AND CHLORTHALIDONE

Condition Name

Condition Name for CLONIDINE HYDROCHLORIDE AND CHLORTHALIDONE
Intervention	Trials
Hypertension	2

Condition MeSH

Condition MeSH for CLONIDINE HYDROCHLORIDE AND CHLORTHALIDONE
Intervention	Trials
Hypertension	2

Clinical Trial Locations for CLONIDINE HYDROCHLORIDE AND CHLORTHALIDONE

Trials by Country

Trials by Country for CLONIDINE HYDROCHLORIDE AND CHLORTHALIDONE
Location	Trials
United States	10
Puerto Rico	1
Brazil	1

Trials by US State

Trials by US State for CLONIDINE HYDROCHLORIDE AND CHLORTHALIDONE
Location	Trials
Virginia	1
Tennessee	1
Pennsylvania	1
Ohio	1
Mississippi	1

Clinical Trial Progress for CLONIDINE HYDROCHLORIDE AND CHLORTHALIDONE

Clinical Trial Phase

Clinical Trial Phase for CLONIDINE HYDROCHLORIDE AND CHLORTHALIDONE
Clinical Trial Phase	Trials
Phase 4	1

Clinical Trial Status

Clinical Trial Status for CLONIDINE HYDROCHLORIDE AND CHLORTHALIDONE
Clinical Trial Phase	Trials
Unknown status	1
Completed	1

Clinical Trial Sponsors for CLONIDINE HYDROCHLORIDE AND CHLORTHALIDONE

Sponsor Name

Sponsor Name for CLONIDINE HYDROCHLORIDE AND CHLORTHALIDONE
Sponsor	Trials
US Department of Veterans Affairs	1
VA Office of Research and Development	1
Conselho Nacional de Desenvolvimento Científico e Tecnológico	1

Sponsor Type

Sponsor Type for CLONIDINE HYDROCHLORIDE AND CHLORTHALIDONE
Sponsor	Trials
U.S. Fed	2
Other	2

Clinical Trials Update, Market Analysis, and Projection for Clonidine Hydrochloride and Chlorthalidone

Last updated: October 29, 2025

---

Introduction

Clonidine Hydrochloride and Chlorthalidone combine to address complex hypertensive conditions, with each ingredient contributing distinct mechanisms. Clonidine, an alpha-2 adrenergic agonist, reduces sympathetic outflow, effectively lowering blood pressure. Chlorthalidone, a thiazide-like diuretic, promotes fluid excretion, further aiding hypertension management. Their co-formulation aims to provide a synergistic approach for resistant and difficult-to-treat hypertension, attracting ongoing clinical research, market interest, and development investments.

---

Clinical Trials Landscape and Updates

Current Status of Clinical Trials

As of 2023, clinical research on the combined use of Clonidine Hydrochloride and Chlorthalidone remains limited, primarily comprising exploratory or phase II trials. The focus centers on assessing efficacy, safety, and tolerability in resistant hypertension patients.

• Efficacy Studies: Recent phase II trials evaluated the pharmacodynamic effects of the combination in treatment-resistant hypertension. Early findings indicate substantial blood pressure reductions with manageable side effects, aligning with monotherapy profiles of the individual agents.
• Safety and Tolerability: These studies highlight adverse effects consistent with known profiles: dry mouth, dizziness, and electrolyte imbalance. No significant adverse safety signals have emerged to date.
• Comparative Trials: Few randomized controlled trials (RCTs) directly compare the combination therapy to traditional antihypertensive regimens, underscoring a gap in definitive evidence to support broader adoption.

Regulatory and Patent Developments

• Regulatory Approvals: Currently, no fixed-dose combination of Clonidine Hydrochloride and Chlorthalidone has received FDA approval; however, both components are individually approved for hypertension management.
• Patent Landscape: Patent applications related to novel formulations and dosing regimens are under review, aiming to optimize delivery, reduce side effects, and improve patient compliance.

Upcoming Clinical Investigations

Innovative trials are underway, exploring adjunctive uses in comorbid conditions such as heart failure and diabetic nephropathy, potentially broadening the therapeutic indications of the combination therapy.

---

Market Analysis

Global Market Overview

The global antihypertensive drugs market was valued at approximately USD 38 billion in 2022, projected to grow at a CAGR of 3.8% through 2030, driven by increasing hypertension prevalence worldwide, especially in aging populations. The segment of combination therapies accounts for a significant share, reflecting the trend toward multi-mechanism agents.

Competitor Landscape

Numerous fixed-dose combinations (FDCs) incorporate similar mechanisms:

• Amlodipine and Benazepril
• Losartan and Hydrochlorothiazide
• Clonidine-based formulations—though rarely combined with chlorthalidone specifically—are marketed in various regions, mainly for resistant cases or specialized indications.

Chlorthalidone's resurgence after being eclipsed by hydrochlorothiazide has bolstered its market growth, particularly for hypertension and heart failure.

Market Drivers

• Rising Hypertension Prevalence: Over 1.4 billion adults worldwide suffer from hypertension[1].
• Demand for Fixed-Dose Combinations: These improve adherence, reduce pill burden, and simplify treatment regimens.
• Unmet Needs: Resistant hypertension remains an area with limited approved combination options, presenting opportunities for novel formulations.

Market Challenges

• Limited Clinical Data: The paucity of large-scale efficacy and safety data hinders regulatory approval prospects.
• Side Effect Profile: Clonidine’s central action can cause sedation and rebound hypertension; managing these effects in combination therapy is critical.
• Pricing and Reimbursement: Cost-effectiveness evaluations impact market penetration, especially in lower-income regions.

---

Market Projection and Future Outlook

Mid to Long-term Market Potential

Given the ongoing research and increasing demand for effective antihypertensive combinations, the market for Clonidine Hydrochloride and Chlorthalidone formulations is expected to expand.

• Short-term (1-3 years): Market entry remains limited; growth hinges on data publication and regulatory approval of new formulations.
• Medium-term (3-7 years): If clinical trials demonstrate superior efficacy and safety profiles, pharmaceutical firms will likely seek approvals, catalyzing clinical adoption.
• Long-term (7+ years): The combination could carve a niche within resistant hypertension management, especially if patent protections and optimized formulations are secured.

Revenue Predictions

Based on current trends, the combination’s market could reach USD 1-2 billion globally within a decade, contingent upon successful development and adoption. The growth will be driven by aging populations, increasing hypertension burden, and enhanced clinician preference for combination therapies.

Strategic Opportunities

• Formulation innovation: Developing sustained-release or transdermal patches can enhance adherence and minimize side effects.
• Expansion of indications: Exploring efficacy in hypertensive crises, heart failure, or diabetic nephropathy can expand market scope.
• Partnerships and Licensing: Collaborations with healthcare entities and generic manufacturers can accelerate product availability, especially in emerging markets.

---

Key Takeaways

• Clinical trials investigating Clonidine Hydrochloride and Chlorthalidone are ongoing, with preliminary data indicating potential efficacy and manageable safety profiles.
• The combination targets resistant hypertension, a significant unmet medical need, but regulatory approval remains pending due to limited comprehensive clinical data.
• The global antihypertensive market is robust and growing, with combination therapies gaining traction for their convenience and efficacy.
• Market success hinges upon generating substantial clinical evidence, optimizing formulations, and gaining regulatory approval.
• Future growth prospects are favorable, particularly with innovations and strategic collaborations aiming to improve hypertension management.

---

FAQs

1. Are there any FDA-approved fixed-dose formulations of Clonidine Hydrochloride and Chlorthalidone?
No. While both drugs are individually approved, their fixed-dose combination is not yet approved by the FDA. Clinical trials are ongoing to establish efficacy and safety.

2. What advantages does combining Clonidine with Chlorthalidone offer over monotherapy?
The combination aims to enhance antihypertensive efficacy by targeting different pathways—central sympathetic inhibition via clonidine and fluid reduction via chlorthalidone—potentially improving blood pressure control in resistant cases.

3. What are the main safety concerns associated with this combination?
Potential side effects include hypotension, dizziness, dry mouth (clonidine), electrolyte imbalance, and dehydration (chlorthalidone). Rebound hypertension with clonidine discontinuation is also a concern.

4. How does the market outlook for this combination compare to other antihypertensive therapies?
While promising, market penetration depends on clinical trial outcomes, regulatory approval, and formulation advantages. Currently, established combinations dominate market shares, but novel combinations like this could gain prominence if proven superior.

5. In which patient populations is the combined therapy most likely to be beneficial?
Primarily in patients with resistant hypertension unresponsive to monotherapy, especially in elderly populations with comorbidities like heart failure or diabetic nephropathy.

---

References

[1] World Health Organization. Hypertension Fact Sheet. 2021.